Shares of Allena Pharmaceuticals Inc (NASDAQ:ALNA) have received a consensus rating of “Buy” from the eight brokerages that are covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $25.20.
ALNA has been the topic of a number of recent research reports. Wedbush reiterated a “buy” rating and set a $39.00 target price on shares of Allena Pharmaceuticals in a research note on Sunday, March 10th. B. Riley set a $22.00 target price on Allena Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, March 8th. Zacks Investment Research upgraded Allena Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a research note on Wednesday, May 8th. Finally, Cowen reiterated a “buy” rating on shares of Allena Pharmaceuticals in a research note on Friday, May 10th.
Institutional investors have recently bought and sold shares of the business. Rhumbline Advisers bought a new position in Allena Pharmaceuticals during the 4th quarter worth $78,000. Renaissance Technologies LLC bought a new position in Allena Pharmaceuticals during the 1st quarter worth $104,000. State of Wisconsin Investment Board increased its stake in Allena Pharmaceuticals by 30.0% during the 1st quarter. State of Wisconsin Investment Board now owns 15,600 shares of the company’s stock worth $110,000 after acquiring an additional 3,600 shares during the period. Wells Fargo & Company MN increased its stake in Allena Pharmaceuticals by 51.9% during the 1st quarter. Wells Fargo & Company MN now owns 21,311 shares of the company’s stock worth $150,000 after acquiring an additional 7,283 shares during the period. Finally, Deutsche Bank AG increased its stake in Allena Pharmaceuticals by 8.2% during the 4th quarter. Deutsche Bank AG now owns 28,023 shares of the company’s stock worth $151,000 after acquiring an additional 2,118 shares during the period. Hedge funds and other institutional investors own 79.71% of the company’s stock.
Allena Pharmaceuticals (NASDAQ:ALNA) last announced its earnings results on Wednesday, May 8th. The company reported ($0.55) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.49) by ($0.06). Analysts forecast that Allena Pharmaceuticals will post -2.05 EPS for the current year.
Allena Pharmaceuticals Company Profile
Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.
See Also: Momentum Investing
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.